Nir Hacohen

Aug 26, 2024 | nature.com | Meghan J. Mooradian |Florian J. Fintelmann |Thomas LaSalle |Alexander Graur |Sophia Z. Shalhout |Howard L. Kaufman | +4 more

AbstractImage-guided percutaneous cryoablation is an established minimally invasive oncologic treatment. We hypothesized that cryoablation may modify the immune microenvironment through direct modulation of the tumor, thereby generating an anti-tumor response in tumors refractory to immune checkpoint inhibition (ICI).

Mar 20, 2024 | broadinstitute.org | Nir Hacohen

Most patients with cancer who are treated with immunotherapies called PD-1 inhibitors don’t respond to the treatments and many researchers have been trying to figure out why by studying immune cells in human tumors. Scientists at the Broad Institute of MIT and Harvard, Brigham and Womens’ Hospital, and Massachusetts General Hospital (MGH) focused on non-small cell lung cancer, the leading cause of cancer death.

Aug 31, 2023 | nature.com | Caleb A Lareau |Leif S. Ludwig |Christoph Muus |Gad Getz |fei chen |Jason D. Buenrostro | +3 more

Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-020-0645-6. Published online 12 August 2020. In the version of this article initially published, due to a coding error, cell clonotypes and allele frequencies were permuted, impacting the visualization of panels in Fig. 6i, j, k, and o. Corrected panels appear as Fig. 1 below, and the software and documentation listed in the Code availability section have been updated.

Apr 18, 2023 | lungcancer.einnews.com | Gad Getz |Nir Hacohen

One of the newest types of cancer drugs, immunotherapies called immune checkpoint inhibitors, has transformed the treatment of lung cancer over the last decade — dramatically improving the survival of some patients with the most common form of this disease, non-small cell lung cancer (NSCLC). However, only about 20 percent of patients experience a benefit from these immunotherapies.